Answers are grounded in this paper and cite their sources.
INTRODUCTION: Large-scale safety data for newly introduced bevacizumab biosimilars in routine oncology practice remain limited. As part of post-marketing safety evaluations under the Risk Management Plan in Japan, we evaluated the risk of venous thromboembolism (VTE) associated with a bevacizumab biosimilar (CTNK) and compared the findings with those for a reference biologic (Avastin®) in Japanese patients with cancer. METHODS: In this retrospective cohort study using a large-scale hospital-based claims database (Medical Data Vision) in Japan, we identified new users of bevacizumab diagnosed with colorectal, breast, or ovarian cancer or glioblastoma between November 2020 and February 2025. Patients were classified into the biosimilar group or the reference biologic group. The primary outcome was the incidence of VTE, evaluated using a multivariable Cox proportional hazards model. Exploratory safety outcomes, including bleeding/hemorrhage and infections, were also assessed. RESULTS: A total of 8599 eligible patients (1967 in the biosimilar group and 6632 in the reference biologic group; male versus female patients, 45.60% and 41.74% versus 54.40% and 58.26%, respectively; median age, 69.0 years in both groups) were included in the primary analysis. The overall incidence of VTE was 2.36%. The adjusted hazard ratio for VTE in the biosimilar group compared with that in the reference biologic group was 0.82 (95% confidence interval, 0.57-1.19; P = 0.30), indicating no significant difference. This finding was consistent across subgroups stratified by target cancer type or by VTE history. Furthermore, the incidence of exploratory safety events was comparable between the two treatment groups. CONCLUSIONS: This retrospective cohort study showed no evidence of increased VTE risk with the bevacizumab biosimilar or major safety differences between the bevacizumab biosimilar and the reference biologic in Japanese patients with cancer, providing reassuring real-world evidence supporting the safe use of the bevacizumab biosimilar in routine clinical practice. Graphical abstract available for this article. TRIAL REGISTRATION: Japan Registry of Clinical Trials identifier, jRCT2031250738, retrospectively registered on February 13, 2026.
No takes yet. Share an insight, caveat, or question.
Ooba et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: